1.北京中医药大学东直门医院,北京市东城区海运仓5号,100700
2.山东中医药大学第一临床医学院
gshb3176@126.com,15810035728
收稿:2022-03-21,
修回:2022-06-30,
纸质出版:2022-10-02
移动端阅览
李贺,吴圣贤,姬寒蕊等.内消软脉汤2号治疗颈动脉粥样硬化斑块痰瘀互结证的实用性随机对照研究[J].中医杂志,2022,63(19):1853-1858.
李贺,吴圣贤,姬寒蕊等.内消软脉汤2号治疗颈动脉粥样硬化斑块痰瘀互结证的实用性随机对照研究[J].中医杂志,2022,63(19):1853-1858. DOI: 10.13288/j.11-2166/r.2022.19.011.
目的
2
评价内消软脉汤2号及其联合他汀类药物治疗颈动脉粥样硬化斑块痰瘀互结证的有效性及安全性。
方法
2
采用实用性随机对照方法,纳入颈动脉粥样硬化斑块痰瘀互结证患者36例,随机分为治疗组与对照组各18例。治疗组给予内消软脉汤2号颗粒剂,每日1剂分2次冲服;对照组在治疗组的基础上同时给予阿托伐他汀钙片口服,每次20 mg,每日1次。两组均连续治疗24周。治疗前后检测两组患者颈动脉最大斑块的横切厚度、斑块面积,计算颈动脉狭窄率并评价临床疗效;检测血脂[包括总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)],检测安全性指标肝功能[包括丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)]、肾功能[包括血尿素氮(BUN)、血肌酐(Cr)]并记录不良事件发生情况。
结果
2
治疗组临床疗效有效率为66.67%(12例/18例),对照组为77.78%(14例/18例),对照组较治疗组提高但两组比较差异无统计学意义(
P
>0.05)。治疗后两组最大斑块横切厚度均较本组治疗前下降(
P
<0.05)。两组患者治疗前后颈动脉最大斑块面积、颈动脉狭窄率、LDL-C、TG、TC、HDL-C、ALT、BUN及Cr水平比较差异均无统计学意义(
P
>0.05);治疗后对照组AST水平较治疗前升高(
P
<0.05)。两组患者在用药期间均未发生不良事件。
结论
2
内消软脉汤2号及其联合他汀类药物治疗均可有效降低颈动脉粥样硬化斑块的厚度,但联合他汀类药物治疗可能会导致AST升高。
Objective
2
To evaluate the effect and safety of
Neixiao Ruanmai Decoction Ⅱ
(内消软脉汤2号, NRD-
Ⅱ
) and its combination with statins in the treatment of carotid atherosclerotic plaque with binding of phlegm and stasis syndrome.
Methods
2
In a pragmatic randomized controlled trial design, 36 carotid atherosclerotic plaque patients with binding of phlegm and stasis syndrome were divided into treatment group (18 cases) and control group (18 cases). The treatment group was given NRD-
Ⅱ
granule, 1 bag for twice a day, and the control group was additionally given oral atorvastatin calcium tablets, 20 mg each time, once a day, both for 24 weeks. The cross-sectional thickness, plaque area, stenosis rate and clinical effect were evaluated before and after treatment. Blood lipid indicators including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), the safety-related liver function indicators including alanine aminotransfe-rase (ALT) and aspartate aminotransferase (AST) and kidney function indicators including blood urea nitrogen (BUN) and serum creatinine (Cr) were assessed, and the adverse events were recorded.
Results
2
The effective rate was 77.78% (14/18) in the control group, higher than 66.67% (12/18) in the treatment group, but with no signi-ficant difference between groups (
P
>0.05). The cross-sectional thickness significantly decreased in both groups after treatment (
P
<0.05). The maximum plaque area of the carotid artery, the carotid stenosis rate, the LDL-C, TG, TC, HDL-C, ALT, BUN and Cr levels were not significantly different in both groups after treatment (
P
>0.05). The AST level in the control group increased after treatment (
P
<0.05). There were no adverse events in both groups during medication period.
Conclusion
2
Both NRD-
Ⅱ
alone and its combination with statins can effectively reduce the thickness of carotid atherosclerotic plaque, but the combination of statins may be associated with the increase of AST level.
LI F , YANG L , YANG R , et al . Ischemic stroke in young adults of northern China: characteristics and risk factors for recurrence [J]. Eur Neurol , 2017 , 77 ( 3/4 ): 115 - 122 .
LI Z , JIANG Y , LI H , et al . China's response to the rising stroke burden [J]. BMJ , 2019 , 28 ( 364 ): l879 . doi: 10. 1136/bmj.l879 http://dx.doi.org/10.1136/bmj.l879 .
闻迪 . 脑梗死与颈动脉粥样硬化斑块的相关性研究 [J]. 中国继续医学教育 , 2020 , 12 ( 15 ): 110 - 111 .
刘丽华 . 彩超检查颈动脉斑块和狭窄与缺血性脑卒中的相关性研究 [J]. 影像研究与医学应用 , 2019 , 3 ( 18 ): 75 - 76 .
ZHOU M , WANG H , ZHU J , et al . Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 [J]. Lancet , 2016 , 387 ( 10015 ): 251 - 272 .
GBD 2016 Causes of Death Collaborators . Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet , 2017 , 390 ( 10100 ): 1151 - 1210 .
陈大伟 , 石进 . 再论无症状性颈动脉狭窄的血管内治疗 [J]. 中华老年心脑血管病杂志 , 2019 , 21 ( 12 ): 1233 - 1235 .
SPENCE JD , NAYLOR AR . Endarterectomy, stenting, or neither for asymptomatic carotid-artery stenosis [J]. N Engl J Med , 2016 , 374 ( 11 ): 1087 - 1088 .
TIWARI V , KHOKHAR M . Mechanism of action of anti-hypercholester-olemia drugs and their resistance [J]. Eur J Pharmacol , 2014 , 741 ( 2014 ): 156 - 170 .
REINER Z . Resistance and intolerance to statins [J]. Nutr Metab Cardiovasc Dis , 2014 , 24 ( 10 ) : 1057 - 1066 .
ZHAO SP , YU BL , PENG DQ , et al . The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial [J]. Atherosclerosis , 2014 , 233 ( 2 ): 707 - 712 .
陈焱 , 李清 . 他汀类药物诱导的肌毒性与临床合理用药 [J]. 中国临床新医学 , 2021 , 14 ( 10 ): 964 - 969 .
李艳 , 张宝琴 , 吕丽敏 . 体检人群血脂水平与动脉粥样硬化的关系探究 [J]. 数理医药学杂志 , 2021 , 34 ( 11 ): 1723 - 1724 .
周华东 , 王延江 , 张猛 . 中国头颈部动脉粥样硬化诊治共识 [J]. 中华神经科杂志 , 2017 , 50 ( 8 ): 572 - 578 .
刘欣燕 , 杨延龙 , 顾秦五风 , 等 . 化痰通络汤对颈动脉粥样硬化患者血管内皮功能及斑块稳定的影响 [J]. 现代中西医结合杂志 , 2021 , 30 ( 35 ): 3925 - 3929 .
郭凯航 , 东潇博 , 郭蓉娟 . 化痰活血法联合常规西医治疗颈动脉粥样硬化疗效的Meta分析 [J]. 中西医结合心脑血管病杂志 , 2020 , 18 ( 17 ): 2762 - 2768 .
吴圣贤 , 何芳 , 武荣荣 . 以“脉生痰核”理论指导动脉粥样硬化研究 [J]. 中医杂志 , 2017 , 58 ( 3 ): 262 - 264 .
苏文全 , 武荣荣 , 高树彪 , 等 . 内消软脉汤治疗颈动脉粥样硬化斑块的随机、双盲、安慰剂平行对照研究 [J]. 中华中医药杂志 , 2021 , 36 ( 10 ): 6233 - 6237 .
华扬 , 惠品晶 , 邢瑛琦 . 中国脑卒中血管超声检查指导规范 [J]. 中华医学超声杂志 , 2015 , 12 ( 8 ): 599 - 610 .
中华中医药学会 . 中药治疗颈动脉粥样硬化临床随机对照试验设计与评价技术规范(2021版) [EB/OL].( 2021-02-25 )[ 2022-03-01 ]. www.cacm.org.cn/2021/02/25/11904 www.cacm.org.cn/2021/02/25/11904 .
吴圣贤 , 王成祥 . 临床研究样本含量估算 [M]. 北京 : 人民卫生出版社 , 2008 : 30 .
杜雅薇 , 吴圣贤 . 从“痰核”论治动脉粥样硬化稳定斑块 [J]. 中国中医基础医学杂志 , 2018 , 24 ( 8 ): 1153 - 1155 .
王可彬 , 马莲 , 吴圣贤 . 从“毒损脉络”论治动脉粥样硬化易损斑块 [J]. 中医药学报 , 2018 , 46 ( 5 ): 5 - 7 .
苏文全 , 杜雅薇 , 吴圣贤 . 吴圣贤分期论治易损斑块经验 [J]. 中医学报 , 2020 , 35 ( 3 ): 600 - 603 .
苏文全 , 吴圣贤 , 杜雅薇 . 从“脉生痰核”论治动脉粥样硬化 [J]. 中医学报 , 2019 , 34 ( 8 ): 1617 - 1620 .
0
浏览量
0
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号